Clinical Trial

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 28, 2025 (before its estimated January 3, 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluate the objective response rate (ORR) of AK104 combined with chemotherapy and cetuximab or bevacizumab in second-line treatment of MSS type advanced colorectal cancer
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07253896
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Safety
Enrollment 40 participants
Start Date 2024-01-03
Primary Completion 2026-01-03 (estimated)
Study Completion 2027-01-03 (estimated)
Updated on ClinicalTrials.gov 2025-11-28